and it's supposed to do a better job than Lutetium (Pluvicto)
But keep an eye also on 64 Cu SAR Bispsma, which had some incredible results, and of course Actinium....honestly on paper they all seem to be better than Lutetium, well, after all we are evolving...
TB-161 does look really interesting. Unlike Lutetium-177 it gives off high LET auger electrons that can act over short distances that should kill micromets which is the main reason lutetium isn't durable and is just a palliative. It's also much easier to produce than lutetium, so should be cheaper and more plentiful. I'm kind of surprised that it didn't get looked at before lutetium-177 given its better overall performance. If this or Actinium or Astatine finally reach the market, they'll make lutetium obsolete.
I know that there are always exceptiona responders...but here is a gift for you (in case you haven't read about this before): guoncologynow.com/post/comp... 😀
I saw that about CU-67. And when you look at CU-67 next to TB-161, the numbers for TB-161 look much more impressive at the level of small volumes down around 5-10 microns where single cells in micrometastasis live.
With low SE's and high efficacy to destroy cancer at the cellular level, it would be nice to see these novel Radiogland treatments approved for earlier use in Standard of Care Protocols. Having to go through and fail palliative ADT and Chemo treatments with all their physically destructive SE's to get to something effective is frustrating.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.